David T. Weaver
10Patents
3h-index
20Co-inventors
56Inventor score
Filing activity: Apr 2, 2004 → Nov 25, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7217794B2 | Compounds and methods for treatment of thrombosis | Human Necessities | 89 | Expired |
| US8343489B2 | Methods for humanizing antibodies and humanized antibodies made thereby | Chemistry; Metallurgy | 7 | Active |
| US8486895B2 | Anti-epidermal growth factor receptor antibodies and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US10532056B2 | Therapeutic compositions, combinations, and methods of use | Chemistry; Metallurgy | 3 | Active |
| US9403913B2 | Anti-VASA antibodies, and methods of production and use thereof | Physics | 1 | Active |
| US11564927B2 | Therapeutic compositions, combinations, and methods of use | Chemistry; Metallurgy | 0 | Active |
| US9028832B2 | Humanized anti-EGFR antibody L4-H3 and coding gene thereof | Chemistry; Metallurgy | 0 | Active |
| US8653244B2 | Anti-epidermal growth factor receptor antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US10738310B2 | Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor | Physics | 0 | Active |
| US9567404B2 | Anti-vasa antibodies, and methods of production and use thereof | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.